BR112022013720A2 - Mutante fimh, composições com o mesmo e seu uso - Google Patents
Mutante fimh, composições com o mesmo e seu usoInfo
- Publication number
- BR112022013720A2 BR112022013720A2 BR112022013720A BR112022013720A BR112022013720A2 BR 112022013720 A2 BR112022013720 A2 BR 112022013720A2 BR 112022013720 A BR112022013720 A BR 112022013720A BR 112022013720 A BR112022013720 A BR 112022013720A BR 112022013720 A2 BR112022013720 A2 BR 112022013720A2
- Authority
- BR
- Brazil
- Prior art keywords
- fimh
- compositions
- mutant
- polypeptides
- lectin domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20152217 | 2020-01-16 | ||
| PCT/EP2021/050707 WO2021144369A1 (en) | 2020-01-16 | 2021-01-14 | Fimh mutant, compositions therewith and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013720A2 true BR112022013720A2 (pt) | 2022-10-11 |
Family
ID=69174406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013720A BR112022013720A2 (pt) | 2020-01-16 | 2021-01-14 | Mutante fimh, composições com o mesmo e seu uso |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11421003B2 (enExample) |
| EP (2) | EP4090363B1 (enExample) |
| JP (2) | JP7485771B2 (enExample) |
| KR (1) | KR20220128372A (enExample) |
| CN (1) | CN115038461A (enExample) |
| AR (1) | AR121066A1 (enExample) |
| AU (1) | AU2021208493B2 (enExample) |
| BR (1) | BR112022013720A2 (enExample) |
| CA (1) | CA3168108A1 (enExample) |
| DK (1) | DK4090363T3 (enExample) |
| ES (1) | ES2987890T3 (enExample) |
| FI (1) | FI4090363T3 (enExample) |
| HR (1) | HRP20241370T1 (enExample) |
| HU (1) | HUE068985T2 (enExample) |
| IL (1) | IL294445B2 (enExample) |
| LT (1) | LT4090363T (enExample) |
| MX (1) | MX2022008830A (enExample) |
| MY (1) | MY209568A (enExample) |
| PL (1) | PL4090363T3 (enExample) |
| PT (1) | PT4090363T (enExample) |
| RS (1) | RS66031B1 (enExample) |
| SA (1) | SA522433319B1 (enExample) |
| SI (1) | SI4090363T1 (enExample) |
| TW (1) | TWI868297B (enExample) |
| WO (1) | WO2021144369A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2021144369A1 (en) | 2020-01-16 | 2021-07-22 | Janssen Pharmaceuticals, Inc. | Fimh mutant, compositions therewith and use thereof |
| CA3173729A1 (en) | 2020-02-23 | 2021-08-26 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| TW202241929A (zh) | 2021-01-12 | 2022-11-01 | 美商詹森藥物公司 | ＦｉｍＨ突變體、其組成物及其用途 |
| EP4448002A1 (en) * | 2021-12-17 | 2024-10-23 | Pfizer Inc. | Polynucleotide compositions and uses thereof |
| AU2023274371A1 (en) | 2022-05-25 | 2024-10-31 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| JP7656656B2 (ja) * | 2022-06-20 | 2025-04-03 | ファイザー・インク | 大腸菌ＦｉｍＨ変異体およびその使用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| JPH0655749B2 (ja) | 1989-09-20 | 1994-07-27 | 日本たばこ産業株式会社 | リピッドａ単糖類縁体 |
| US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
| US5593969A (en) | 1991-09-03 | 1997-01-14 | Igen Incorporated | Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors |
| EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| CA2284586C (en) | 1997-04-01 | 2011-02-08 | Ribi Immunochem Research, Inc. | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
| US6500434B1 (en) | 1998-04-23 | 2002-12-31 | Medimmune, Inc. | Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections |
| US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
| CZ301212B6 (cs) | 1998-10-16 | 2009-12-09 | Smithkline Beecham Biologicals S. A. | Vakcinacní prostredek |
| WO2001025254A2 (en) | 1999-10-04 | 2001-04-12 | University Of Maryland Biotechnology Institute | Novel adjuvant comprising a lipopolysaccharide antagonist |
| WO2001078777A2 (en) | 2000-04-13 | 2001-10-25 | Mossman, Sally | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 |
| JP2004502447A (ja) | 2000-07-07 | 2004-01-29 | メディミューン，インコーポレイテッド | ＦｉｍＨアドへシンタンパク質および使用方法 |
| EP1313502A4 (en) | 2000-08-18 | 2005-10-19 | Medimmune Inc | ADMINISTRATIVE PROCEDURE OF FIMH PROTEIN AS A VACCINE AGAINST HARNWAY INFECTIONS |
| WO2002102974A2 (en) | 2000-12-08 | 2002-12-27 | Medimmune, Inc. | Mutant proteins, high potency inhibitory antibodies and fimch crystal structure |
| US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
| CN101355928B (zh) | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
| JP5356807B2 (ja) | 2005-05-11 | 2013-12-04 | アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ | 原核細胞由来の組み換えｎ−グリコシル化タンパク質 |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| HRP20181259T1 (hr) | 2008-02-20 | 2018-10-05 | Glaxosmithkline Biologicals S.A. | Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica |
| LT2437753T (lt) | 2009-06-05 | 2016-12-12 | Infectious Disease Research Institute | Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos |
| US11510875B2 (en) | 2012-02-07 | 2022-11-29 | Access To Advanced Health Institute | Adjuvant formulations comprising TLR4 agonists and methods of using the same |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| US9415097B2 (en) | 2013-09-25 | 2016-08-16 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9017698B2 (en) | 2013-09-25 | 2015-04-28 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9415101B2 (en) | 2013-09-25 | 2016-08-16 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149522B2 (en) * | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| EA035991B9 (ru) | 2014-02-24 | 2020-10-21 | Глаксосмитклайн Байолоджикалс С.А. | Новый полисахарид и его применения |
| EP3693379A1 (en) * | 2015-05-13 | 2020-08-12 | University of Washington | Compositions and methods for treatment and prevention of uropathogenice. coli |
| EA039065B1 (ru) | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| TW201946650A (zh) | 2018-03-12 | 2019-12-16 | 美商詹森藥物公司 | 針對腹內感染之疫苗 |
| EP4077372A1 (en) | 2019-12-20 | 2022-10-26 | Vib Vzw | Nanobody exchange chromatography |
| WO2021144369A1 (en) | 2020-01-16 | 2021-07-22 | Janssen Pharmaceuticals, Inc. | Fimh mutant, compositions therewith and use thereof |
| TW202241929A (zh) | 2021-01-12 | 2022-11-01 | 美商詹森藥物公司 | ＦｉｍＨ突變體、其組成物及其用途 |
-
2021
- 2021-01-14 WO PCT/EP2021/050707 patent/WO2021144369A1/en not_active Ceased
- 2021-01-14 SI SI202130194T patent/SI4090363T1/sl unknown
- 2021-01-14 JP JP2022542383A patent/JP7485771B2/ja active Active
- 2021-01-14 PL PL21700027.2T patent/PL4090363T3/pl unknown
- 2021-01-14 PT PT217000272T patent/PT4090363T/pt unknown
- 2021-01-14 RS RS20241096A patent/RS66031B1/sr unknown
- 2021-01-14 EP EP21700027.2A patent/EP4090363B1/en active Active
- 2021-01-14 KR KR1020227026828A patent/KR20220128372A/ko active Pending
- 2021-01-14 EP EP24189800.6A patent/EP4461744A3/en active Pending
- 2021-01-14 MX MX2022008830A patent/MX2022008830A/es unknown
- 2021-01-14 AU AU2021208493A patent/AU2021208493B2/en active Active
- 2021-01-14 IL IL294445A patent/IL294445B2/en unknown
- 2021-01-14 CN CN202180009530.0A patent/CN115038461A/zh active Pending
- 2021-01-14 FI FIEP21700027.2T patent/FI4090363T3/fi active
- 2021-01-14 MY MYPI2022003755A patent/MY209568A/en unknown
- 2021-01-14 ES ES21700027T patent/ES2987890T3/es active Active
- 2021-01-14 BR BR112022013720A patent/BR112022013720A2/pt unknown
- 2021-01-14 HU HUE21700027A patent/HUE068985T2/hu unknown
- 2021-01-14 HR HRP20241370TT patent/HRP20241370T1/hr unknown
- 2021-01-14 DK DK21700027.2T patent/DK4090363T3/da active
- 2021-01-14 CA CA3168108A patent/CA3168108A1/en active Pending
- 2021-01-14 LT LTEPPCT/EP2021/050707T patent/LT4090363T/lt unknown
- 2021-01-15 US US17/150,025 patent/US11421003B2/en active Active
- 2021-01-15 AR ARP210100099A patent/AR121066A1/es unknown
- 2021-01-15 TW TW110101729A patent/TWI868297B/zh active
-
2022
- 2022-07-16 SA SA522433319A patent/SA522433319B1/ar unknown
- 2022-07-26 US US17/814,966 patent/US12012435B2/en active Active
-
2023
- 2023-12-26 JP JP2023218988A patent/JP2024045126A/ja active Pending
-
2024
- 2024-05-06 US US18/655,708 patent/US12428449B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022013720A2 (pt) | Mutante fimh, composições com o mesmo e seu uso | |
| BR112022022456A2 (pt) | Proteínas de ligação de repetição de anquirina e seus usos | |
| BR112022011177A2 (pt) | Domínios de repetição de anquirina projetados com resíduos de superfície alterados | |
| BR112022009679A2 (pt) | Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos | |
| BR112022019492A2 (pt) | Inibidores de rip1k | |
| BR112022020629A2 (pt) | Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção | |
| BRPI0717156B8 (pt) | inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende | |
| BR112018072915A2 (pt) | peptídeo cíclico isolado e composição farmacêutica | |
| BR112017017530A2 (pt) | proteínas específicas para pioverdina e pioquelina | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| BR112015021414A2 (pt) | vírus da doença newcastle e seus usos | |
| BR112021006598A2 (pt) | composição farmacêutica líquida, e, kit | |
| BR112016028520A2 (pt) | métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina | |
| BR112018017031A2 (pt) | formulações de antagonista de il-6 e usos das mesmas | |
| BR112017016200A8 (pt) | Método para produzir hidrogéis conjugando módulo de alta elasticidade e absorvência | |
| BR112017026292A2 (pt) | muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico | |
| BR112017025728A2 (pt) | fragmentos mutantes da proteína ras | |
| BR112019008349A2 (pt) | composição de peptídeos, e, utilização de uma composição. | |
| CO2020010193A2 (es) | Una composición farmacéutica para la anemia | |
| BR112021021230A8 (pt) | Forma de cristal de composto inibidor de wee1 e uso do mesmo | |
| MX2023008251A (es) | Mutantes de fimh, composiciones con estos y uso de estos. | |
| BR112016011930A2 (pt) | combinações de peptídeos e seus usos em tratamento de alergia de ácaro de poeira | |
| BR112021020883A2 (pt) | Formas sólidas de um inibidor de glyt1 | |
| BR112019007543A2 (pt) | inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase | |
| MX2021011596A (es) | Compuestos y composiciones como moduladores de se?alizacion tlr. |